GENIXUS, a pharmaceutical company focused on transforming emergency and critical care medicines, announced the completion of a $20 million funding round to support the development and commercialization of its new ready-to-use product line for hospital environments.
"We are delighted to complete this funding in early 2022," said Kendall Foster, founder and CEO of GENIXUS. This new funding allows us to significantly accelerate our development projects and establish our production and commercial activities in preparation for the launch of our products."
GENIXUS completed the expansion of its aseptic production facility in Kannapolis in 2021. The latest round of funding support further increases in personnel and infrastructure, both to expand production capacity and improve the company's ability to produce and commercialize future sterile injection product lines. Seth Coombs, co-founder and chief commercial officer of GENIXUS, noted: "This funding puts us in a strong position to grow in 2022. With these funds, we can move our work forward quickly, simplifying acute and critical care products to support the best patient care across the United States."
GENIXUS is a pharmaceutical company in the development phase dedicated to changing acute and critical care medicines through advanced production and innovative delivery systems. Leveraging the highest quality biopharmaceutical manufacturing standards and innovative point-of-care design, GENIXUS is transforming care delivery and helping healthcare professionals achieve better quality outcomes for patients.